Results 221 to 230 of about 40,773 (330)

An Anti-PCSK9 Antibody Reduces LDL-Cholesterol On Top Of A Statin And Suppresses Hepatocyte SREBP-Regulated Genes [PDF]

, 2012
Liwen Zhang, Timothy J. McCabe, Jon H. Condra, Ni Yan, Laurence B. Peterson, Weirong Wang, Alison M. Strack, Fubao Wang, Shilpa Pandit, Holly A. Hammond, Dana D. Wood, Dale Lewis, Ray Rosa, Vivienne Mendoza, Anne Marie Cumiskey, Douglas G. Johns, Barbara C. Hansen, Xun Shen, Neil S. Geoghagen, Kristian K. Jensen, Lei Zhu, Karol Wietecha, Douglas Wisniewski, Lingyi Huang, Jing Zhao, Robin Ernst, Richard Hampton, Peter Haytko, Frances Ansbro, Shannon Chilewski, Jayne Chin, Lyndon J. Mitnaul, Andrea Pellacani, Carl P. Sparrow, Zhiqiang An, William R. Strohl, Brian K. Hubbard, Andrew Plump, Daniël Blom, Ayesha Sitlani   +39 more
openalex   +1 more source

Erster PCSK9-Hemmer [PDF]

MMW - Fortschritte der Medizin, 2016
openaire   +3 more sources

Design and Rationale of the LAPLACE‐TIMI 57 Trial: A Phase II, Double‐Blind, Placebo‐Controlled Study of the Efficacy and Tolerability of a Monoclonal Antibody Inhibitor of PCSK9 in Subjects With Hypercholesterolemia on Background Statin Therapy [PDF]

, 2012
Payal Kohli, Nihar R. Desai, Robert P. Giugliano, Jae Bum Kim, Ransi Somaratne, Fannie Huang, Beat Knüsel, Shannon T McDonald, Timothy E Abrahamsen, Scott M. Wasserman, Robert C. Scott, Marc S. Sabatine   +11 more
openalex   +1 more source

PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE[S]

Journal of Lipid Research, 2014
LDL cholesterol (LDL-C) contributes to coronary heart disease. Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases LDL-C by inhibiting LDL-C clearance.
Brandon Ason, José W.A. van der Hoorn, Joyce Chan, Edward Lee, Elsbet J. Pieterman, Kathy Khanh Nguyen, Mei Di, Susan Shetterly, Jie Tang, Wen-Chen Yeh, Margrit Schwarz, J. Wouter Jukema, Rob Scott, Scott M. Wasserman, Hans M.G. Princen, Simon Jackson   +15 more
doaj  

Elevated PCSK9 Levels in Untreated Patients With Heterozygous or Homozygous Familial Hypercholesterolemia and the Response to High‐Dose Statin Therapy [PDF]

, 2013
Frederick J. Raal, Vanessa R. Panz, A Immelman, Gillian J. Pilcher   +3 more
openalex   +1 more source

The interrelations between PCSK9 metabolism and cholesterol synthesis and absorption

Journal of Lipid Research, 2019
Very few studies have investigated the interrelations between proprotein convertase subtilisin/kexin type 9 (PCSK9) metabolism, cholesterol synthesis, and cholesterol absorption.
Günther Silbernagel, Lars K. Steiner, Tim Hollstein, Günter Fauler, Hubert Scharnagl, Tatjana Stojakovic, Friederike Schumann, Bediha Bölükbasi, Winfried März, Elisabeth Steinhagen-Thiessen, Ulrich Laufs, Ursula Kassner   +11 more
doaj  

Plasma PCSK9 Is a Late Biomarker of Severity in Patients With Severe Trauma Injury [PDF]

, 2013
M. Le Bras, Antoine Roquilly, Valérie Deckert, Cédric Langhi, Fanny Feuillet, Véronique Sébille, Pierre-Joachim Mahé, K. Bach, Damien Masson, Laurent Lagrost, Philippe Costet, Karim Asehnoune, Bertrand Cariou   +12 more
openalex   +1 more source

B001 PCSK9 deficient mice are not protected against hypercholesterolemia when fed a high fat diet

, 2009
Cédric Le May, Bertrand Cariou, Phillipe Costet   +2 more
openalex   +1 more source

Exploring the Pleiotropy of PCSK9: A Wide Range of Influences from Lipid Regulation to Extrahepatic Function. [PDF]

J Inflamm Res
Wang H, Tang G, Wu J, Qin X.
europepmc   +1 more source

PCSK9 Manipulates Lipid Metabolism and the Immune Microenvironment in Cancer. [PDF]

Onco Targets Ther
Cui C, Yan A, Huang S, Chen Y, Zhao J, Li C, Wang X, Yang J.   +7 more
europepmc   +1 more source